Search

Your search keyword '"Carrier, Lucie"' showing total 622 results

Search Constraints

Start Over You searched for: Author "Carrier, Lucie" Remove constraint Author: "Carrier, Lucie" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
622 results on '"Carrier, Lucie"'

Search Results

2. Western diet triggers cardiac dysfunction in heterozygous Mybpc3-targeted knock-in mice: A two-hit model of hypertrophic cardiomyopathy

3. Abstract 12927: Impact of AAV-MYBPC3 Gene Transfer on Heart Structure and Function in Human and Mouse Models of Hypertrophic Cardiomyopathy

4. Cas9-expressing chickens and pigs as resources for genome editing in livestock

6. Broad therapeutic benefit of myosin inhibition in hypertrophic cardiomyopathy

8. Translational investigation of electrophysiology in hypertrophic cardiomyopathy

11. RNA Editing Holds Promise for Hypertrophic Cardiomyopathy Therapy.

13. Targets for therapy in sarcomeric cardiomyopathies

16. EGFR/IGF1R Signaling Modulates Relaxation in Hypertrophic Cardiomyopathy

20. Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy

22. Reducing microtubule detyrosination improves heart function in HCM mice and human iPSC-engineered heart tissues

23. Animal models and animal-free innovations for cardiovascular research

24. Nitro-fatty acids suppress ischemic ventricular arrhythmias by preserving calcium homeostasis

32. Modelling LMNA-cardiomyopathy with patient-specific human iPSC-derived engineered heart tissue and a partial rescue by gene replacement therapy

35. Functional characterisation of a patient-derived laminopathy model in human engineered heart tissues recapitulates fibrosis and mechanical decoupling defect

37. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: From molecular mechanisms to therapeutic targets

39. ACTN2 Mutant Causes Proteopathy in Human iPSC-Derived Cardiomyocytes

40. Disease modeling of a mutation in α‐actinin 2 guides clinical therapy in hypertrophic cardiomyopathy

44. CMYA5 is a novel interaction partner of FHL2 in cardiac myocytes

45. Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics

46. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)

47. Autophagy

50. ACTN2mutant causes proteopathy in human iPSC-derived cardiomyocytes

Catalog

Books, media, physical & digital resources